{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:22:37Z","timestamp":1791408157332,"version":"4.3.3"},"reference-count":23,"publisher":"Japan Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0713","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T18:06:58Z","timestamp":1751911618000},"page":"1143-1150","source":"Crossref","is-referenced-by-count":3,"title":["Potentially fatal crisis after &lt;sup&gt;177&lt;\/sup&gt;Lu-DOTATATE therapy for paraganglioma: a case report with review of literature"],"prefix":"10.1507","volume":"72","author":[{"given":"Aoki","family":"Tobimatsu","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9365-5561","authenticated-orcid":false,"given":"Kosuke","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-3635","authenticated-orcid":false,"given":"Yoshinari","family":"Obata","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-3020","authenticated-orcid":false,"given":"Kayako","family":"Isohashi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7499-9919","authenticated-orcid":false,"given":"Kazuyuki","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6289-3778","authenticated-orcid":false,"given":"Atsunori","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"},{"name":"Department of Adipose Management, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0838-6772","authenticated-orcid":false,"given":"Hiroki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Radiology, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-9603","authenticated-orcid":false,"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, et al. (2022) Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 33: 90\u2013114.","DOI":"10.1007\/s12022-022-09704-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Fischer A, Kloos S, Maccio U, Friemel J, Remde H, et al. (2023) Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses. J Clin Endocrinol Metab 108: 2676\u20132685.","DOI":"10.1210\/clinem\/dgad166"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Neumann HPH, Young WF Jr, Eng C (2019) Pheochromocytoma and paraganglioma. N Engl J Med 381: 552\u2013565.","DOI":"10.1056\/NEJMra1806651"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Marretta AL, Ottaiano A, Iervolino D, Bracigliano A, Clemente O, et al. (2023) Response to peptide receptor radionuclide therapy in pheocromocytomas and paragangliomas: a systematic review and meta-analysis. J Clin Med 12: 1494.","DOI":"10.3390\/jcm12041494"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Tang CYL, Chua WM, Huang HL, Lam WW, Loh LM, et al. (2023) Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: a single-institution experience and review of the literature. J Neuroendocrinol 35: e13349.","DOI":"10.1111\/jne.13349"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Kornerup LS, Andreassen M, Knigge U, Arveschoug AK, Poulsen PL, et al. (2024) Effects of peptide receptor radiotherapy in patients with advanced paraganglioma and pheochromocytoma: a nation-wide cohort study. Cancers (Basel) 16: 1349.","DOI":"10.3390\/cancers16071349"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, et al. (2020) Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 38: 1443\u20131456.","DOI":"10.1097\/HJH.0000000000002438"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, et al. (2017) Phase 3 trial of <sup>177<\/sup>Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376: 125\u2013135.","DOI":"10.1056\/NEJMoa1607427"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Prado-Wohlwend S, Del Olmo-Garc\u00eda MI, Bello-Arques P, Merino-Torres JF (2022) Response to targeted radionuclide therapy with [<sup>131<\/sup>I]MIBG AND [<sup>177<\/sup>Lu]Lu-DOTA-TATE according to adrenal <i>vs.<\/i> extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: a systematic review. Front Endocrinol (Lausanne) 13: 957172.","DOI":"10.3389\/fendo.2022.957172"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, et al. (2003) Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956\u2013962; discussion 962\u2013953.","DOI":"10.1016\/S0039-6060(03)00426-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Zandee WT, Feelders RA, Smit Duijzentkunst DA, Hofland J, Metselaar RM, et al. (2019) Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using <sup>177<\/sup>Lu-DOTATATE. Eur J Endocrinol 181: 45\u201353.","DOI":"10.1530\/EJE-18-0901"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Vyakaranam AR, Crona J, Norl\u00e9n O, Granberg D, Garske-Rom\u00e1n U, et al. (2019) Favorable outcome in patients with pheochromocytoma and paraganglioma treated with <sup>177<\/sup>Lu-DOTATATE. Cancers (Basel) 11: 909.","DOI":"10.3390\/cancers11070909"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, et al. (2008) Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [<sup>177<\/sup>Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 35: 749\u2013755.","DOI":"10.1007\/s00259-007-0691-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Makis W, McCann K, McEwan AJ (2015) The challenges of treating paraganglioma patients with <sup>177<\/sup>Lu-DOTATATE PRRT: catecholamine crises, tumor lysis syndrome and the need for modification of treatment protocols. Nucl Med Mol Imaging 49: 223\u2013230.","DOI":"10.1007\/s13139-015-0332-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Malaza G, Brofferio A, Lin F, Pacak K (2019) Ivabradine in catecholamine-induced tachycardia in a patient with paraganglioma. N Engl J Med 380: 1284\u20131286.","DOI":"10.1056\/NEJMc1817267"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Phelps TE, Del Rivero J, Chertow DS, Rosing D, Pacak K, et al. (2024) Managing catecholamine release syndrome during and following Lu-177-DOTATATE in high-risk pheochromocytoma patients. JCEM Case Rep 2: luae049.","DOI":"10.1210\/jcemcr\/luae049"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Gubbi S, Al-Jundi M, Auh S, Jha A, Zou J, et al. (2023) Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [<sup>177<\/sup>Lu]Lu-DOTA-TATE therapy. Front Endocrinol (Lausanne) 14: 1275813.","DOI":"10.3389\/fendo.2023.1275813"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Makuuchi Y, Wada M, Kawashima A, Kataoka Y, Miyahara M, et al. (2015) Paraganglioma-induced alveolar hemorrhage. Intern Med 54: 487\u2013489.","DOI":"10.2169\/internalmedicine.54.2304"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Zhai Q, Tian C, Deng Z, Liu C, Ma Q (2021) Case report: an unusual first manifestation of a pheochromocytoma. Front Endocrinol (Lausanne) 12: 697202.","DOI":"10.3389\/fendo.2021.697202"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Nezu M, Kobayashi H, Shiozaki M, Katsumata M, Takizawa S, et al. (2021) Pheochromocytoma diagnosed during the treatment of diffuse alveolar hemorrhage, a diagnostic necessity before using high-dose glucocorticoids. Intern Med 60: 2825\u20132830.","DOI":"10.2169\/internalmedicine.6827-20"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Suematsu R, Miyata J, Sano T, Watanabe C, Maki Y, et al. (2021) Diffuse alveolar hemorrhage associated with dilated cardiomyopathy and sleep apnea syndrome. Intern Med 60: 1911\u20131914.","DOI":"10.2169\/internalmedicine.5219-20"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Del Olmo-Garc\u00eda MI, Muros MA, L\u00f3pez-de-la-Torre M, Agudelo M, Bello P, et al. (2020) Prevention and management of hormonal crisis during theragnosis with LU-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal. J Clin Med 9: 2203.","DOI":"10.3390\/jcm9072203"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Tsang ES, Funk G, Leung J, Kalish G, Kennecke HF (2021) Supportive management of patients with advanced pheochromocytomas and paragangliomas receiving PRRT. Curr Oncol 28: 2823\u20132829.","DOI":"10.3390\/curroncol28040247"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/10\/72_EJ24-0713\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:55:46Z","timestamp":1759550146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/10\/72_EJ24-0713\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0713","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0713"}}